1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine.

Slides:



Advertisements
Similar presentations
Practicalities of Palliative Care
Advertisements

Gold standards Framework and prognostication
Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University
What is Pneumonia and How Do I Prevent it?
Oncology and Palliative Care: Promoting the Comfort and Cure Model Parag Bharadwaj, MD FAAHPM.
Can Comparative Effectiveness Study Tell Us What Is The Best Therapy For Class IV Heart Failure? Beta blockers or LVADs?
Monica Colvin-Adams, MD Assistant Professor of Medicine Advanced Heart Failure and Transplantation University of Minnesota Compassionate Allowances Outreach.
Estimating Benefit in Ambulatory Heart Failure Patients MedaMACS Progress Report 2014 Garrick C. Stewart, MD Brigham and Women’s Hospital.
1 Heart Failure William Chavey, MD, MS Associate Professor Department of Family Medicine University of Michigan.
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz,
Prepared by : Nehad J. Ahmed.  Heart failure, also known as congestive heart failure (CHF), means your heart can't pump enough blood to meet your body's.
The Heart and Heart Failure in the Year 2013 Jonathan D. Rich, MD Associate Director, Mechanical Circulatory Support Program Bluhm Cardiovascular Institute.
Between May 2013 and June 2014, we implanted the C-Pulse device in 7 male and 1 female patients with a mean age ± SD of 61.1 ± 9.4 years. Four had ischemic.
Case Studies Advanced Heart Failure and the Role of Mechanical Circulatory Support Megan Shifrin, RN, MSN, ACNP-BC Vanderbilt University.
Congestive Heart Failure (CHF)
Dean Handimulya UIEU 2005 Congestive Heart Failure Dean Handimulya, M.D.
Heart Failure Whistle Stop Talks No. 2 Classification Implications Susie Bowell BA Hons, RGN Heart Failure Specialist Nurse.
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Joseph G. Rogers, MD Professor of Medicine Duke University
Heart Failure Ben Starnes MD FACC Interventional Cardiology
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults p.o.box zip code Done by: Dr.Amin Zagzoog.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
An International Case Study of Lung Transplantation
Treatment of Heart Failure: Beyond Medical Therapy
Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.
Indication and contra-indications for cardiac catheterization
Community Health Team Care Management Process PinnacleHealth Systems Don DeArmitt, M.D. Becky E. Zook RN, BSN, MS, CCP.
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
HeartWare HVAD: Risk Factors for Adverse Outcomes Mark S. Slaughter, MD Professor and Chair Department Cardiovascular and Thoracic Surgery University of.
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
BECOMING COMFORTABLE with HOSPICE. Hospice Goals: Understand hospice comfortably Able to discuss hospice with the patient & family Know when and how to.
Prognostic Indicator Guidance May 2011 Dr Peter Nightingale.
Heart Failure Supportive Care in 2015 GIL KIMEL MD, MSC, FRCPC Dept. of Medicine St. Paul’s Hospital.
Heart Failure Palliative Care/Heart Failure Audit.
Intervention in end-stage heart failure. Is it ever too late ? Can you solve my problem ?
Cardiac Failure Richard Price Richard Price Consultant, Intensive Care, RAH. Consultant, Intensive Care, RAH.
Department of CTVS.  56 years old male from Cuttack  Date of admission  Date of surgery  Date of death  Diagnosis:
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical.
TREATMENT OF HEART FAILURE From Oral Medications to Intravenous Drips Mark Puhlman MSN ANP.
Palliative Care In Heart Failure Dr Chi-Chi Cheung Consultant in Palliative Medicine 19 th March 2015.
Heart Failure Devices: Staying Connected Lisa D. Rathman, MSN, CRNP, CCRN, CHFN The Heart Group of Lancaster General Health Lancaster, PA.
Advanced Therapies Lee R. Goldberg, MD, MPH Medical Director, Heart Failure and Cardiac Transplant Program University of Pennsylvania.
Mechanical Circulatory Support in Special Populations Renzo Y. Loyaga-Rendon MD.,PhD.. Assistant Professor Advanced Heart Failure Section University of.
Extracorporeal Membrane Oxygenation for Bridge to Decision and to Recovery Shigeki Tabata, Hitoshi Hirose, Nicholas C. Cavarocchi, James T. Diehl, Hiroyuki.
Michael S Kiernan, MD, SM Assistant Professor, Tufts University Medical Director Ventricular Assist Device Program, Tufts Medical Center.
Patient Selection & Risk Stratification Soltani GH, MD.
Cardio-Pulmonary Pre Operative Risk Assessment Andy Shakespeare MD PGY2 Baylor Scott and White IM
Primary Mitral Regurgitation Degenerative Mitral Valve Disease
Ridha Chakeer MD PGY3. Objectives: Approximately 5.2 million Americans are affected  accounts for more than 3 million outpatient visits to primary care.
Palliative Care Education Module
Dr Dylan Harris Dr Mel Jefferson
Sepsis Surgeon Champions Talking Points
University of Chicago Medicine
University of Cincinnati Medical Center
Ventricular function recovery on LVAD For idiopathic or ischemic CM
Assist Devices for the Treatment of Cardiogenic Shock
Role of ECMO in Acute Cardiogenic Shock
Hospice in Hospital - GIP and Beyond
Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,
COPD Exacerbations UCI Internal Medicine Mini-Lecture
Calculate Well’s score for PE (BOX1)
Perspectives in Palliative Care
New Models of Care in Idiopathic Pulmonary Fibrosis
The Heart Failure Nurse Service
Case 5 Revision surgery after pertrochanteric fracture
Presentation transcript:

1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School

PATIENT 1 Onset heart failure at age 70 Normal coronary arteries Optimal oral medical management Resynchronization ICD Recurrent hospitalizations for heart failure and VT EF < 10 % LVEDD 7.5 cm 2

PATIENT 1 Age 72 Improvement with milrinone –Creatinine 0.9 –Albumin 3.7 –INR 1.2 –RA 12 (2-5) –PCW 22 (5-12) –RVSWI 832 (>600) Recurrence of symptoms off milrinone 3

WHAT DO YOU RECOMMEND 1. Hospice 2. Bridge to hospice with milrinone 3. Long term home milrinone 4. Heart transplant 5. Mechanical circulatory support 4

OUTCOMES OF CONTINUOUS HOME MILRINONE THERAPY Group1 yr survBaseline NYHA6 m NYHA (if alive) Bridge to TX/VAD83.3%3.892 Weaning strategy Palliative care Muthsusamy, JHLT 2012, 31:S14

Figure 12 Source: The Journal of Heart and Lung Transplantation 2012; 31: ( DOI: /j.healun ) The Journal of Heart and Lung Transplantation 2012; 31: TRANSPLANT SURVIVAL BY AGE

~240 Million US Population ≥ 20 years old 6.24 Million HF = 2.6% of the population 3.12 Million Systolic HF = 50% of HF population 124,800 Adv. Stage C / NYHA IIIB Advanced Stage C = 3-4% 156,000 Stage D / NYHA IV = 0.5-5% 70,200 Potential candidates for transplant THE PROBLEM 2000 heart transplants per year Courtesy John O’Connell, MD

DURABLE MECHANICAL CIRCULATORY SUPPORT 8

ASSESSING THE BENEFIT HEARTMATE II RISK SCORE x age – x albumin x creatinine x INR for centers with > 15 implants per year – = Cowger, JACC, 2013

HEARTMATE II RISK SCORE 10 Cowger, JACC, 2013

PATIENT 1 11

PATIENT 2 72 years old male Diabetic CAD Prior CABG and mitral valve repair Recurrent hospitalizations for heart failure 30 lb weight loss Creatinine 2.9 Albumin 3.0 INR

WHAT DO YOU RECOMMEND 13 1.Hospice 2.Bridge to hospice with milrinone 3. Long term home milrinone 4. Heart transplant 5. Mechanical circulatory support

SURVIVAL IN HEART FAILURE No CKD CKD Age Age > Hospitalizations Median Survival (years) Setoguchi, Am Heart J 2007

PATIENT 2 HEARTMATE II RISK SCORE x age – x albumin x creatinine x INR for centers with > 15 implants per year – =

HEARTMATE II RISK SCORE 16 Cowger, JACC 2013

17 ProfileDescriptionTime to MCS 1“Crashing and burning” - critical cardiogenic shock.Within hours 2 “Progressive decline” – inotrope dependence with continuing deterioration. Within a few days 3 “Stable but inotrope dependent” - describes clinical stability on mild- moderate doses of intravenous inotropes. (Patients stable on temporary circulatory support without inotropes are within this profile). Within a few weeks 4 “Recurrent advanced heart failure” - “recurrent” rather than “refractory” decompensation. Within weeks to months 5 “Exertion intolerant” - describes patients who are comfortable at rest but are exercise intolerant. Variable 6 “Exertion limited” – a patient who is able to do some mild activity but fatigue results within a few minutes or any meaningful physical exertion. Variable 7 “Advanced ” - describes patients who are clinically stable with a reasonable level of comfortable activity, despite history of previous decompensation that is not recent. Not a candidate for MCS

SURVIVAL TO DISCHARGE 18 Boyle JHLT 2011

LENGTH OF STAY 19 Boyle JHLT 2011

RISK FACTORS FOR EARLY DEATH Risk FactorHazard RatioP-value Prior stroke Prior CABG1.84< INTERMACS INTERMACS BiVAD3.27< Prior valve surgery Kirklin, JHLT 2012, 31:117

OTHER CONSIDERATIONS Support system Understand the risks Understand the lifestyle Desire to proceed Ability to interpret and act on alarms Understand options including palliative care 21

22 PATIENT 3 30 years old ODU graduate Program Development Director for Muscular Dystrophy Association Bought a condo Acquired a small dog Progressive cough and dyspnea for 6 weeks Couldn’t carry dog up the steps Diagnosis – bronchitis, reflux 2 courses of outpatient antibiotics Sent to ER by PCP for pneumonia

23 1. Bilateral lower lobe air space opacities with effusions, right greater than left. Findings may be related to multifocal pneumonia or aspiration. Recommend radiographic follow-up to clearance. 2. Mildly enlarged cardiac silhouette

HOSPITALIST ASSESSMENT 24 Assessment: Patient Active Hospital Problem List: *Community Acquired Pneumonia (4/13/2010) GERD (Gastroesophageal Reflux Disease) (4/13/2010) Fatigue (4/13/2010) Anxiety (4/13/2010) Plan: Treat for CAP. Prn nebulizer treatments. Prn xanax for anxiety. Continue home celexa. Recommend repeat imaging during her hospital course.

HOSPITAL COURSE Respiratory arrest at 11 AM on 4/14 Cardiac arrest at 12 noon Ejection fraction – 5-10% by echo Persistent shock despite norepinephrine, dobutamine Creatinine 1.1 INR 1.58 Albumin 3.1 SGOT 1158 Lactate

WHAT DO YOU DO 1. Continue medical management 2. Intraaortic balloon pump 3. Temporary mechanical circulatory support 4. Durable mechanical circulatory support 5. Palliative care 26

SHOCK II 27

HOSPITAL COURSE Referred to Advanced Heart Failure Team at 2:30 PM Briefly staibilized with intraaortic balloon pump Progressive deterioration over next 30 min To OR at 6:30PM for Acute Mechanical Circulatory Support Regained consciousness End organ function recovered Heart transplant 5/3/

Saturday, May 22, days post transplant

PATIENT 4 28 years old male Air Force veteran 4-6 month history progressive deterioration 3 week history of nausea, abdominal pain, vomiting Admitted to local hospital on 6/26/2012 INR 6.1 Creatinine 2.7 Albumin

31

PATIENT 4 Diagnosis: acute liver failure, acute renal failure Vitamin K, FFP Considered urgent referral for liver transplant Cardiopulmonary arrest 6/27 EF 5-10% Medical management Transferred to SNGH 6/28/2012 for acute mechanical circulatory support 32

MANAGEMENT OPTIONS 1. Continue medical management 2. Intraaortic balloon pump 3. Temporary mechanical circulatory support 4. Durable mechanical circulatory support 5. Palliative care 33

PATIENT 4 CentriMag temporary support device Restoration of circulation Changout to durable device Fungal device infection Recovery of cardiac function Device explant Death from multiorgan failure and heart failure Family asks if earlier transfer would have changed outcome 34

WHAT’S THE DIFFERENCE Same heart Same age Case 4 –Late presentation –Later referral –Irreversible end-organ damage Where do you draw the line? 35

SUMMARY Durable mechanical circulatory –Referral before progressive renal or liver dysfunction –Referral before pressors are required –Referral before cardiac cachexia develops Acute, temporary mechanical circulatory support –Early recognition before irreversible end-organ damage –Early referral –Early initiation of mechanical support –Families of young, healthy patients who die are litiginous 36

WHO HAS THE VAD? 37